Laboratory fundamentals · 6 min
What a Certificate of Analysis can—and cannot—tell you
How identity, purity, analytical method and batch provenance work together.
The EternaGen research library
Science, without
the sensationalism.
Explore factual study context, compound documentation and research practices—clearly separated from product recommendations.
Research methods · 11 minFeatured research guide
Reading peptide research with a critical eye
A practical framework for separating trial design, observed outcomes and unsupported interpretation.
Read the guide
Protocol series · 8 min
Compound integrity from storage to analysis
A documentation-first approach to controlled storage and laboratory handling.
Clinical-trial index · 9 min
How EternaGen reports published clinical-trial information
Our standard for factual summaries, source citation and separation from commerce.
Traceability · 5 min
Why one batch should always lead to one record
The information architecture behind transparent compound documentation.
Primary-source registry
Evidence, with its limits attached.
Each record identifies what investigators studied, who participated and what the publication cannot establish. Study context is never converted into a product recommendation.
Randomized human trialTesamorelin
Growth hormone-releasing factor in adults with HIV-associated abdominal fat accumulation
- Design
- Randomized, double-blind, placebo-controlled study with a 12-month extension
- Population
- 404 adults living with HIV and excess abdominal fat in the context of antiretroviral therapy
- Study context
- The investigators examined visceral adipose tissue, body-composition measures, participant-reported outcomes and safety measures.
- Interpretation limit
- The findings apply to the defined trial population and do not establish outcomes for other populations or research materials.
Phase 2 human trialRetatrutide
Triple-hormone-receptor agonist retatrutide studied in adults with obesity
- Design
- Randomized, double-blind, placebo-controlled phase 2 trial over 48 weeks
- Population
- 338 adults with obesity
- Study context
- The prespecified endpoints included percentage change in body weight and safety observations across trial groups.
- Interpretation limit
- Retatrutide was investigational in this study; trial findings are not a recommendation or evidence about non-trial products.
Translational studyMOTS-c
Exercise-associated MOTS-c biology across animal models and a small human sample
- Design
- Mechanistic experiments with animal models plus exercise sampling in humans
- Population
- The human component included 10 young male participants
- Study context
- The study examined endogenous MOTS-c expression in skeletal muscle and circulation following exercise.
- Interpretation limit
- This was not a therapeutic human trial and cannot establish clinical efficacy, safety or an appropriate intervention.
Phase 2 human trialIpamorelin
Ipamorelin studied for postoperative gastrointestinal recovery
- Design
- Multicentre, randomized, double-blind, placebo-controlled proof-of-concept trial
- Population
- 117 adults undergoing bowel resection were enrolled
- Study context
- The investigators evaluated postoperative recovery endpoints and safety in a hospital setting.
- Interpretation limit
- The study reported no significant differences in its key or secondary efficacy analyses.
Educational source index only. Publication summaries do not constitute medical advice, therapeutic claims or recommendations for human or veterinary use.
EternaGen protocol series